187 related articles for article (PubMed ID: 35822405)
21. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort.
Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL
Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872
[TBL] [Abstract][Full Text] [Related]
22. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
Tie J; Cohen JD; Lo SN; Wang Y; Li L; Christie M; Lee M; Wong R; Kosmider S; Skinner I; Wong HL; Lee B; Burge ME; Yip D; Karapetis CS; Price TJ; Tebbutt NC; Haydon AM; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Popoli M; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Int J Cancer; 2021 Feb; 148(4):1014-1026. PubMed ID: 32984952
[TBL] [Abstract][Full Text] [Related]
24. A Blood Test for Methylated BCAT1 and IKZF1 vs. a Fecal Immunochemical Test for Detection of Colorectal Neoplasia.
Symonds EL; Pedersen SK; Baker RT; Murray DH; Gaur S; Cole SR; Gopalsamy G; Mangira D; LaPointe LC; Young GP
Clin Transl Gastroenterol; 2016 Jan; 7(1):e137. PubMed ID: 26765125
[TBL] [Abstract][Full Text] [Related]
25. Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNA.
Wang W; Zhu X; Zhang X; Lei C; Zeng Z; Lan X; Cui W; Wang F; Xu S; Zhou J; Wu X; Deng H; Li X; Fan J; Ding Y; Huang Z; Liang L
J Pathol; 2023 Apr; 259(4):376-387. PubMed ID: 36573552
[TBL] [Abstract][Full Text] [Related]
26. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
[TBL] [Abstract][Full Text] [Related]
27. Low Sensitivity of Fecal Immunochemical Tests and Blood-Based Markers of DNA Hypermethylation for Detection of Sessile Serrated Adenomas/Polyps.
Cock C; Anwar S; Byrne SE; Meng R; Pedersen S; Fraser RJL; Young GP; Symonds EL
Dig Dis Sci; 2019 Sep; 64(9):2555-2562. PubMed ID: 30835026
[TBL] [Abstract][Full Text] [Related]
28. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
Parikh AR; Chee BH; Tsai J; Rich TA; Price KS; Patel SA; Zhang L; Ibrahim F; Esquivel M; Van Seventer EE; Jarnagin JX; Raymond VM; Corvera CU; Hirose K; Nakakura EK; Corcoran RB; Van Loon K; Atreya CE
Clin Cancer Res; 2024 May; ():. PubMed ID: 38695832
[TBL] [Abstract][Full Text] [Related]
29. Prognostic models based on postoperative circulating tumor cells can predict poor tumor recurrence-free survival in patients with stage II-III colorectal cancer.
Wang D; Yang Y; Jin L; Wang J; Zhao X; Wu G; Zhang J; Kou T; Yao H; Zhang Z
J Cancer; 2019; 10(19):4552-4563. PubMed ID: 31528219
[No Abstract] [Full Text] [Related]
30. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
[TBL] [Abstract][Full Text] [Related]
31. The value of circulation tumor DNA in predicting postoperative recurrence of colorectal cancer: a meta-analysis.
Wang R; Zhao A; Cao N; Li Z; Zhang G; Liu F
Int J Colorectal Dis; 2020 Aug; 35(8):1463-1475. PubMed ID: 32572601
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL
Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972
[TBL] [Abstract][Full Text] [Related]
33. Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer.
Adams AM; Vreeland TJ; Newhook TE
J Gastrointest Cancer; 2023 Dec; 54(4):1071-1081. PubMed ID: 36562938
[TBL] [Abstract][Full Text] [Related]
34. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
[TBL] [Abstract][Full Text] [Related]
35. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases.
Bolhuis K; van 't Erve I; Mijnals C; Delis-Van Diemen PM; Huiskens J; Komurcu A; Lopez-Yurda M; van den Broek D; Swijnenburg RJ; Meijer GA; Punt CJA; Fijneman RJA
EBioMedicine; 2021 Aug; 70():103498. PubMed ID: 34333237
[TBL] [Abstract][Full Text] [Related]
36. Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence-a systematic review and meta-analysis.
Chen Y; Mo S; Wu M; Li Y; Chen X; Peng J
Int J Colorectal Dis; 2022 May; 37(5):1021-1027. PubMed ID: 35384496
[TBL] [Abstract][Full Text] [Related]
37. Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer.
Yuan Z; Wang S; Ni K; Zhan Y; Ma H; Liu X; Xin R; Zhou X; Liu Z; Zhao X; Yin X; Ping H; Liu Y; Wang W; Yan S; Han Q; Cui W; Zhang X; Zhang Q; Zhang C
Med Sci Monit; 2022 Sep; 28():e937757. PubMed ID: 36117308
[TBL] [Abstract][Full Text] [Related]
38. Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer.
Nakamura Y; Yokoyama S; Matsuda K; Tamura K; Mitani Y; Iwamoto H; Mizumoto Y; Murakami D; Kitahata Y; Yamaue H
Sci Rep; 2021 Jan; 11(1):441. PubMed ID: 33432066
[TBL] [Abstract][Full Text] [Related]
39. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
40. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
